Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

October 22, 2014

Study Completion Date

June 30, 2020

Conditions
Gastric CancerUnresectable
Interventions
DRUG

Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel

Trial Locations (7)

1090

Universitätsklinik Wien, Vienna

A-6020

Universitätsklinik Innsbruck, Innsbruck

A-8700

A.ö. Landeskrankenhaus Leoben, Leoben

A-4020

Krankenhaus der Stadt Linz, Linz

A-5020

Universitaetsklinik f. Innere Medizin III, Salzburg

A-4600

Klinikum Wels-Grieskirchen GmbH, Wels

A-6511

BKH Zams, Zams

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

Sanofi

INDUSTRY

collaborator

Roche Pharma AG

INDUSTRY

lead

Arbeitsgemeinschaft medikamentoese Tumortherapie

OTHER